Research Nester released a report titled “Pulmonary Fibrosis Drugs Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers detailed overview of the global pulmonary fibrosis drugs market in terms of market segmentation by drug and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Pulmonary Fibrosis is a disorder which affects the lungs by scarring the lung tissues and eventually damaging them. This obstructs the passageway for air and thus hinders the normal functioning of the lungs. The market for pulmonary fibrosis drugs is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. The market is segmented by drug and by region, out of which, the drug segment is further bifurcated into pirfenidone and nintedanib. The segment for pirfenidone is anticipated to hold the largest share in the pulmonary fibrosis drugs market on account of increased usage of the drug ever since it received approval by the Food and Drug Administration (FDA).

On the basis of regional analysis, the pulmonary fibrosis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Pulmonary fibrosis drugs market is predicted to grow at the highest rate in the Asia Pacific region on account of growing presence of leading companies involved in research and development activities for the manufacturing of effective drugs. The market in North America is estimated to hold the leading share in the market as a result of growing research and developments in the area as well as presence of key players in the market in this region.

Rising Cases of Pulmonary Fibrosis as a Result of Genetics to Boost the Market Growth

According to the National Health Service (NHS) in UK, idiopathic pulmonary fibrosis (IPF) commonly affects people between the ages of 70 and 75 years, and it rarely occurs among people under the age of 50 years. Moreover, it states that about 1 in 20 people with IPF have a family history of the disease. The growing cases of people with the disorder are predicted to significantly increase the demand for pulmonary fibrosis drugs, leading to the market growth in the upcoming years. However, the limited number of drugs approved by regulatory bodies is estimated to hinder the market growth over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global pulmonary fibrosis drugs market which includes company profiling of Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd. (SWX: RO), FibroGen, Inc. (NASDAQ: FGEN), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), MediciNova, Inc. (NASDAQ: MNOV), Genentech, Inc., Cipla Inc. (NSE: CIPLA), Biogen (NASDAQ: BIIB) and Galapagos NV (AMS: GLPG). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global pulmonary fibrosis drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.